Design Therapeutics (DSGN) Depreciation & Amortization (CF) (2020 - 2026)
Design Therapeutics recorded quarterly Depreciation & Amortization (CF) of $157000.0 in Q1 2026, up 0.64% quarter-over-quarter from $156000.0 in Q4 2025, and down 1.26% year-over-year from $159000.0 in Q1 2025.
Design Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $157000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 1.26% year-over-year to $157000.0; the TTM figure through Mar 2026 stood at $620000.0 (up 1.31% YoY), while the FY2025 annual figure was $622000.0, up 4.36% from the prior year.
- Depreciation & Amortization (CF) came in at $157000.0 for Q1 2026 at Design Therapeutics, up from $156000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $159000.0 in Q1 2025 to a low of $82000.0 in Q1 2022.
- A 5-year average of $136352.9 and a median of $143000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) soared 1950.0% in 2022 and dropped 1.26% in 2026, its largest moves.
- Design Therapeutics' Depreciation & Amortization (CF) stood at $124000.0 in 2022, then climbed by 11.29% to $138000.0 in 2023, then rose by 7.97% to $149000.0 in 2024, then advanced by 4.7% to $156000.0 in 2025, then gained by 0.64% to $157000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $157000.0, $156000.0, and $155000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | 157,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157,000.00 |
| Mar 31, 2026 | 157,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Sep 30, 2025 | 155,000.00 |
| Sep 30, 2025 | 155,000.00 |
| Jun 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 152,000.00 |
| Mar 31, 2025 | 159,000.00 |
| Mar 31, 2025 | 159,000.00 |
| Dec 31, 2024 | 149,000.00 |
| Dec 31, 2024 | 149,000.00 |
| Sep 30, 2024 | 153,000.00 |
| Sep 30, 2024 | 153,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 143,000.00 |
| Mar 31, 2024 | 143,000.00 |
| Dec 31, 2023 | 138,000.00 |
| Dec 31, 2023 | 138,000.00 |
| Sep 30, 2023 | 137,000.00 |
| Sep 30, 2023 | 137,000.00 |
| Jun 30, 2023 | 133,000.00 |
| Jun 30, 2023 | 133,000.00 |
| Mar 31, 2023 | 129,000.00 |
| Mar 31, 2023 | 129,000.00 |
| Dec 31, 2022 | 124,000.00 |
| Dec 31, 2022 | 124,000.00 |
| Sep 30, 2022 | 108,000.00 |
| Sep 30, 2022 | 108,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Mar 31, 2022 | 82,000.00 |
| Mar 31, 2022 | 82,000.00 |
| Dec 31, 2021 | 82,000.00 |
| Dec 31, 2021 | 82,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | 12,000.00 |
| Jun 30, 2021 | 12,000.00 |
| Mar 31, 2021 | 4,000.00 |
| Mar 31, 2021 | 4,000.00 |
| Dec 31, 2020 | 4,000.00 |
| Dec 31, 2020 | 4,000.00 |